

# Contents

**Contributors** ..... xxiii

**Introduction**.....xxxi

*Myron F. Weiner, M.D.*

*Anne M. Lipton, M.D., Ph.D.*

## PART I

### Assessment and Diagnosis

**1 Neuropsychiatric Assessment and  
Diagnosis** ..... **3**

*Myron F. Weiner, M.D.*

*Robert Garrett, M.D.*

*Mary E. Bret, M.D.*

DSM-IV-TR Cognitive Disorders ..... 4

Normal Cognitive Aging ..... 4

The Complaint of Cognitive Impairment..... 9

Mild Cognitive Impairment..... 10

Dementia ..... 11

Delirium ..... 18

Amnesic Disorder ..... 20

Other Cognitive Disorders ..... 20

Psychiatric Disorders ..... 21

Speech and Language..... 30

Clinical Techniques and Tools for Diagnosing

    Cognitive Dysfunction..... 32

    Characterizing Dementing Illnesses..... 38

    Quantifying Cognitive Impairment..... 39

    Key Clinical Points..... 43

References . . . . .	43
Further Reading . . . . .	46
<b>2 Medical and Neurological Evaluation and Diagnosis . . . . .</b>	<b>47</b>
<i>Anne M. Lipton, M.D., Ph.D.</i>	
<i>Craig D. Rubin, M.D.</i>	
Setting . . . . .	48
History . . . . .	48
Physical Examination . . . . .	53
Neurological Examination . . . . .	53
Laboratory Studies . . . . .	55
Special Diagnostic Procedures . . . . .	56
Other Diagnostic Procedures . . . . .	57
How Much Evaluation Is Enough? . . . . .	60
How Often Are Evaluations Indicated? . . . . .	61
Conclusion . . . . .	61
Key Clinical Points . . . . .	61
References . . . . .	62
Further Reading . . . . .	63
<b>3 Neuropsychological Assessment . . . . .</b>	<b>65</b>
<i>C. Munro Cullum, Ph.D., A.B.P.P.</i>	
<i>Laura H. Lacritz, Ph.D., A.B.P.P.</i>	
Effect of Aging on Cognitive Function . . . . .	66
Comprehensive Neuropsychological Evaluation for Dementia . . . . .	66
Neuropsychological Evaluation of Cognitive Domains . . . . .	68
Neuropsychological Screening Batteries for Dementia . . . . .	79
Interpretation of Neuropsychological Results . . . . .	80
Neuropsychological Profiles in Dementia . . . . .	80
Conclusion . . . . .	84
Key Clinical Points . . . . .	85
References . . . . .	85
Further Reading . . . . .	88

**4 Neuroimaging .....89**

*Norman L. Foster, M.D.*

Rational Use of Neuroimaging in Dementia Care ... .89  
Structural Neuroimaging.....92  
Molecular Neuroimaging .....102  
Special Situations .....114  
Emerging Neuroimaging Methods.....119  
New Neuroimaging Applications.....121  
Key Clinical Points .....122  
References .....123  
Further Reading.....126

**5 Alzheimer Disease .....127**

*David S. Geldmacher, M.D.*

Epidemiology.....127  
Clinical History and Course of Illness .....128  
Mental Status Findings .....136  
Pathology .....146  
Genetics .....151  
Treatment.....154  
Key Clinical Points .....154  
References .....155  
Further Reading.....158

**6 Mild Cognitive Impairment .....159**

*Yonas E. Geda, M.D, M.Sc.*

*Ronald C. Petersen, Ph.D., M.D.*

History .....160  
Progression of MCI to Dementia .....160  
Clinical Features.....161  
Subtypes.....162  
Neuropsychiatric Features .....163  
Neuroimaging .....165  
Neuropathology.....166  
Treatment.....167

Key Clinical Points . . . . .	167
References . . . . .	168
Further Reading . . . . .	170

## **7 Vascular Cognitive Disorder . . . . . 171**

*Cassandra E. I. Szoeké, Ph.D., F.R.A.C.P., M.B.B.S.,  
B.Sc. (Hons.)*

*Stephen Campbell, F.R.A.C.P., M.Ch.B.S., B.Sc.*

*Edmond Chiu, A.M., M.B.B.S., D.P.M., F.R.A.N.Z.C.P.*

*David Ames, B.A., M.D., F.R.C.Psych., F.R.A.N.Z.C.P.*

History . . . . .	172
Diagnostic Criteria . . . . .	172
Subtypes . . . . .	176
Epidemiology . . . . .	178
Genetics . . . . .	179
Etiology . . . . .	180
Assessment . . . . .	183
Treatment . . . . .	185
Outcome . . . . .	185
Conclusion . . . . .	186
Key Clinical Points . . . . .	186
References . . . . .	186
Further Reading . . . . .	191

## **8 Dementia With Lewy Bodies and Other Synucleinopathies . . . . . 193**

*Rawan Tarawneh, M.D.*

*James E. Galvin, M.D., M.Sc.*

Dementia With Lewy Bodies . . . . .	194
Parkinson Disease With Dementia . . . . .	201
Neuropathology . . . . .	204
Diagnostic Evaluation . . . . .	207
Therapeutics . . . . .	208
Conclusion . . . . .	213

Key Clinical Points . . . . .	213
References . . . . .	214
Further Reading . . . . .	218

**9 Frontotemporal Dementia and Other Tauopathies . . . . .219**

*Anne M. Lipton, M.D., Ph.D.*  
*Adam Boxer, M.D., Ph.D.*

History . . . . .	220
Clinical Subtypes of FTD . . . . .	220
Overlap of FTD Clinical Syndromes . . . . .	222
Clinical Syndromes Associated With FTD . . . . .	222
Neuropathology . . . . .	223
Diagnostic Evaluation . . . . .	224
Treatment . . . . .	226
Key Clinical Points . . . . .	228
References . . . . .	228
Further Reading . . . . .	230

**10 Traumatic Brain Injury . . . . .233**

*Erin D. Bigler, Ph.D.*

Proximal Effects of TBI: Dementia Due to Head Trauma . . . . .	234
Neuroimaging for Estimating Severity of Brain Injury in TBI . . . . .	236
Stability of Dementia Due to Head Trauma: Living With Brain Injury and Aging . . . . .	244
Remote Effects of TBI: Relation to Late-Life Neurodegenerative Changes . . . . .	245
Repetitive Head Injuries . . . . .	248
Conclusion . . . . .	250
Key Clinical Points . . . . .	251
References . . . . .	251
Further Reading . . . . .	256

**11 Other Causes of Dementia.....257**

*Edward Y. Zamrini, M.D.*

*Mary Quiceno, M.D.*

Diseases Primarily Affecting  
the Central Nervous System.....258

Diseases Primarily Affecting an Organ Outside the  
Central Nervous System.....271

Diseases Caused by Exposure to  
Toxic Substances.....276

Diseases Due to Deficiency of  
an Essential Substance.....280

Key Clinical Points.....281

References.....281

Further Reading.....285

**PART II  
Treatment**

**12 Treatment of Psychiatric Disorders in  
People With Dementia.....289**

*Martin Steinberg, M.D.*

*Constantine G. Lyketsos, M.D., M.H.S.*

Depression.....290

Psychosis.....294

Apathy.....302

Executive Dysfunction Syndrome.....305

Agitation and Aggression.....308

Key Clinical Points.....312

References.....312

Further Reading.....315

## **13 Pharmacological Treatment of Neuropsychiatric Symptoms . . . . .317**

*Roy Yaari, M.D., M.A.S.*

*Pierre N. Tariot, M.D.*

*Danielle F. Richards*

A Rational Approach to Evaluation . . . . .	318
Nonpharmacological Interventions . . . . .	318
Pharmacological Interventions . . . . .	320
Antidementia Therapies . . . . .	333
Conclusion . . . . .	334
Key Clinical Points . . . . .	334
References . . . . .	335
Further Reading . . . . .	340

## **14 Pharmacological Treatment of Alzheimer Disease and Mild Cognitive Impairment . . . .341**

*Martin R. Farlow, M.D.*

*Malaz Boustani, M.D., M.P.H.*

General Principles . . . . .	342
Cholinergic Augmentation . . . . .	343
NMDA Receptor Antagonists . . . . .	352
Serotonin Augmentation . . . . .	353
Antioxidants . . . . .	357
Ginkgo Biloba . . . . .	358
Treatment of Mild Cognitive Impairment . . . . .	358
Conclusion . . . . .	359
Key Clinical Points . . . . .	359
References . . . . .	360
Further Reading . . . . .	363

**15 Supporting Family Caregivers .....365**

*Kristin Martin-Cook, M.S., C.C.R.C.*

*Myron F. Weiner, M.D.*

Education About the Illness .....366  
Imparting a Psychological Point of View.....372  
Impact of Dementia on the Family .....375  
Caregiver Stress.....379  
Driving .....381  
Sexuality.....382  
Long-Term-Care Placement .....382  
Ethical Issues for Caregivers.....383  
Conclusion .....385  
Key Clinical Points.....385  
References .....386  
Further Reading.....387

**Appendix: Resources .....389**

National Agencies .....389  
State Agencies.....394  
Other Sources of Information.....395

**Index .....397**